You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Multivariate proportional hazards models by treatment arm

From: Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

STAD + RT Arm(n = 45) Endpoints Covariate Comparison HR* 95% CI p-value**
  Overall Survival VEGF 0-1 vs. RL (0.734, 2.745) 0.299
2-3 1.419
Age < 71 vs. RL (0.608, 2.910) 0.475
≥ 71 1.330
Combined Gleason Score 2-6 vs. RL (0.393, 2.581) 0.988
7-10 1.007
Clinical Stage T2 vs. RL (0.213, 1.196) 0.120
T3 0.505
Distant Metastasis VEGF 0-1 vs. RL (0.264, 1.326) 0.200
2-3 0.592
Age < 71 vs. RL (0.813, 6.614) 0.120
≥71 2.318
Combined Gleason Score 2-6 vs. RL (1.622,61.105) 0.013
7-10 9.957
Clinical Stage T2 vs. RL (0.376, 3.580) 0.800
T3 1.160
Local Progression VEGF 0-1vs. RL (0.321, 2.064) 0.660
2-3 0.814
Age < 71 vs. RL ( 0.288, 3.515) 0.990
≥71 1.006
Combined Gleason Score 2-6 vs. RL (0.420, 9.427) 0.390
7-10 1.990
Clinical Stage T2 vs. RL (0.146, 1.755) 0.280
T3 0.506
Disease-free Survival VEGF 0-1vs. RL (0.273, 0.995) 0.048
2-3 0.521
Age < 71 vs. RL (0.807, 3.601) 0.162
≥ 71 1.705
Combined Gleason Score 2-6 vs. RL (0.792, 4.567) 0.150
7-10 1.902
Clinical Stage T2 vs. RL (0.403, 2.054) 0.052
T3 0.910
Biochemical Failure VEGF 0-1vs. RL (0.251, 1.170) 0.120
2-3 0.542
Age < 71 vs. RL (0.805, 3.834) 0.160
≥ 71 1.757
Combined Gleason Score 2-6 vs. RL (0.783, 14.343) 0.100
7-10 3.352
Clinical Stage T2 vs. RL (0.425, 3.151) 0.780
T3 1.157
RT Alone Arm(n = 58) Endpoints Covariate Comparison HR* 95% CI p-value**
Overall Survival VEGF 0-1 vs. RL (0.622, 2.028) 0.699
2-3 1.123
Age < 71 vs. RL (0.890, 2.800) 0.118
≥ 71 1.579
Combined Gleason Score 2-6 vs. RL (0.839, 2.566) 0.178
7-10 1.468
Clinical Stage T2 vs. RL (0.760, 2.917) 0.246
T3 1.489
Distant Metastasis VEGF 0-1 vs. RL (0.777, 3.319) 0.200
2-3 1.606
Age < 71 vs. RL (0.422, 1.706) 0.640
≥71 0.848
Combined Gleason Score 2-6 vs. RL (0.992, 3.825) 0.053
7-10 1.947
Clinical Stage T2 vs. RL (0.357, 1.789) 0.590
T3 0.800
Local Progression VEGF 0-1vs. RL (0.670, 2.669) 0.410
2-3 1.337
Age < 71 vs. RL (0.391, 1.643) 0.540
≥71 0.801
Combined Gleason Score 2-6 vs. RL (0.259, 1.067) 0.075
7-10 0.525
Clinical Stage T2 vs. RL (0.415, 1.971) 0.800
T3 0.905
Disease-free Survival VEGF 0-1vs. RL (0.779, 2.371) 0.279
2-3 1.359
Age < 71 vs. RL (0.305, 0.979) 0.042
≥ 71 0.547
Combined Gleason Score 2-6 vs. RL (1.021, 3.537) 0.043
7-10 1.900
Clinical Stage T2 vs. RL (0.473, 1.913) 0.889
T3 0.952
Biochemical Failure VEGF 0-1vs. RL (0.815, 2.562) 0.210
2-3 1.446
Age < 71 vs. RL (0.315, 1.104) 0.056
≥ 71 0.565
Combined Gleason Score 2-6 vs. RL (0.655, 2.356) 0.510
7-10 1.242
Clinical Stage T2 vs. RL (0.474, 2.459) 0.850
    T3 1.080   
  1. * A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A hazard ratio of 1 indicates no difference between two subgroups.
  2. ** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure) Proportional Hazards Model.
  3. indicates the statistically significant at the significance level of 0.05.
  4. 1 patient without Gleason score is not included.